A Phase 2, Single-Arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date2/03/21 → 1/03/26

Keywords

  • phase 2 study
  • renal cell carcinoma
  • treatment efficacy
  • treatment safety